Meyka AI API is live for developers.Start building.
Advertisement
Eli Lilly and Company

Eli Lilly and Company (LLY) Stock Overview

Explore Eli Lilly and Company’s financial performance, market position, analyst ratings, and future outlook.

LLYNYSE
HealthcareDrug Manufacturers - General
$1131.42
$6.15(0.55%)
U.S. Market opens in 50h 41m
Advertisement

Eli Lilly and Company (LLY)

Meyka AI Score

Z

Key Financials

Market Cap1.1T
P/E Ratio40.20
EPS (TTM)$28.13
ROE1.01%
Fundamental Analysis

AI Price Forecasts

1 Month$811.60
3 Months$827.25
1 Year Target$1152.87

LLY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Eli Lilly and Company (LLY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 68.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1152.87.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 40.20 and a market capitalization of 1.1T. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.69%
5-Day Change
0.53%
1-Month Change
14.58%
3-Month Change
15.23%
6-Month Change
12.14%
Year-to-Date (YTD) Change
5.43%
1-Year Change
47.97%
3-Year Change
155.03%
5-Year Change
409.17%
All-Time (Max) Change
40220.64%

Contact Information

317 276 2000
Lilly Corporate Center, Indianapolis, IN, 46285

Company Facts

47,000 Employees
IPO DateJun 1, 1972
CountryUS
Actively Trading

Frequently Asked Questions